146P HRD/TIL-low high-risk breast cancer is characterized by good prognosis (the RADIMMUNE trial)
B. Pellegrino(Ospedale di Parma), A. Musolino(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), K. Willard-Gallo(Institut Jules Bordet), E. Silini(University of Parma), A. Sikokis(Ospedale di Parma), N. Campanini(University of Parma), C. Casarini(Ospedale di Prato Santo Stefano), M. Michiara(Fondazione IRCCS Istituto Nazionale dei Tumori), M.V. Dieci(University of Padua), J. Balmaña(Vall d'Hebron Hospital Universitari), A. Llop-Guevara(CIBBIM-Nanomedicine), D. Boggiani(University of Parma), G. Zoppoli(University of Genoa), Antonio Frassoldati(Italian Oncology Group of Clinical Research), E. Cretella(Ospedale di Bolzano), C. Tommasi(University of Parma), Violeta Serra(Vall d'Hebron Institute of Oncology), M. Lambertini(Ospedale Policlinico San Martino), C. Solinas(Institut Jules Bordet), L. Cortesi(Azienda Ospedaliero-Universitaria di Modena)
Cited by 1
Related Papers
PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
|Cancer Discovery|2012|622
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
|Oncogene|2011|534
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
|Annals of Oncology|2020|478